Antibody | Target cell | Clone | Dilution | Supplier |
Calprotectin | Monocyte, neutrophil | MAC387 | 1:100 | Neomarkers* |
HLA-DR | LN3 | 1:50 | Novocastra† | |
CD68 | Tissue macrophage | CBL-260 | 1:100 | Cymbus Biotech‡ |
CD3 | T lymphocyte | PS1 | 1:100 | Novocastra† |
CD20 | B lymphocyte | L26 | 1:200 | Novocastra† |
CD1A | Dendritic cell | MTB1 | 1:25 | Novocastra† |
CD31 | Endothelial cell | JC/70A | Prediluted | DAKO§ |
CD34 | Endothelial and haemopoietic stem cells | QBEnd10 | 1:50 | DAKO§ |
Ki67 | Replicating cells | MIB-1 | Prediluted | Zymed¶ |
BMPR2 | Rabbit polyclonal | 1:20 | N Morrell | |
S100A4 | Rabbit polyclonal | 1:2000 | N Ambartsumian |
* Fremont, California, USA. † Newcastle upon Tyne, UK. ‡ Chandlers Ford, UK. § Ely, UK. ¶ San Francisco, California, USA. BMPR2, bone morphogenetic protein type-2 receptor; HLA, human leucocyte antigen.